Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19
23. Februar 2023 09:00 ET
|
InSilico Medicine
New York, Feb. 23, 2023 (GLOBE NEWSWIRE) -- ISM3312 is a highly selective 3CLpro inhibitor with a novel molecular structure optimized from compounds designed by Chemistry42, Insilico’s...